The relevance of real-world data for the evaluation of neuropathic pain treatments

Baron, R., Mick, G. and Serpell, M. (2022) The relevance of real-world data for the evaluation of neuropathic pain treatments. Pain Management, 12(7), pp. 845-857. (doi: 10.2217/pmt-2022-0057) (PMID:36106645)

Abstract

Treatment of neuropathic pain (NP) is challenging. Interest in real-world evidence (RWE) for benefit-risk assessments of NP treatments increases given the paucity of drugs showing efficacy in randomized controlled trials and restricted labels of available medicines. To provide further context, a literature review regarding regulatory use of RWE and a clinical trial registry search for randomized controlled trials over the last 10 years was carried out. Taken together, and especially for available NP treatments, there is increasing support to consider RWE when evaluating their benefit-risk profile. Examples are provided in which RWE could be used effectively for updating the product label and informing treatment recommendations. Collected and analyzed according to state-of-the-art standards, RWE can inform treatment recommendations and product label decisions.

• Item Type: Articles
• Keywords: Perspective, benefit-risk assessment, labeling guidelines, neuropathic pain, real-world evidence, treatment guidelines.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Serpell, Dr Michael
• Authors: Baron, R., Mick, G., and Serpell, M.
• College/School: College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: Pain Management
• Publisher: Future Medicine
• ISSN: 1758-1869
• ISSN (Online): 1758-1877
• Published Online: 15 September 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in Pain Management 12(7): 845-857
• Publisher Policy: Reproduced under a Creative Commons License